AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT01219946
- Locations
- 🇬🇷
Research Site, Xanthi, Traki, Greece
Evaluation of Dapagliflozin Taken Twice-daily
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT01217892
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT01217905
- Locations
- 🇬🇧
Research site, Croydon, United Kingdom
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
Phase 1
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Radiation: 150 mg [14C] AZD6765
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01217645
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT01215305
- Locations
- 🇬🇷
Research Site, Komotini, Thraki, Greece
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseLung Disease
- Interventions
- Drug: Placebo to AZD2423
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 63
- Registration Number
- NCT01215279
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer
Withdrawn
- Conditions
- Gastrointestinal HemorrhageUlcer
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2010-10-22
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01215058
Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
Phase 4
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo matching Seroquel XRDrug: Placebo matching Seroquel IR
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT01213836
- Locations
- 🇪🇸
Research Site, Zamora, Castilla Leon, Spain
A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01214122
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT01214135
- Locations
- 🇸🇪
Research Site, Öjebyn, Sweden